Money incentive

New Report Forecasts More Than Doubling of Vaccine Sales by 2013

Jun 11, 2009

2008 was another stellar year for the world vaccine market. Sales grew
21.5% since 2007 to reach $19.2 billion. Few areas of pharmaceuticals
have seen the fast-moving developments in the marketplace that the
vaccine market has. A new report from leading life science market
research publisher Kalorama Information, "Vaccines 2009: World Market
Analysis, Key Players, and Critical Trends in a Fast-Changing Industry,"
forecasts the market to more than double by 2013 due to a strong pipeline
of new products and rising usage of current products around the world.

    "New products and better-than-expected profits, as well as merger
activity, have transformed the vaccine marketplace," says Bruce Carlson,
publisher of Kalorama Information. "Continued sales of influenza and
cervical cancer vaccines have provided a foundation for growth in the
adult market. Meanwhile, the pediatric market was fueled by several major
products including Wyeth's pneumococcal vaccines Prevnar and Merck's new
rotavirus vaccine TotaTeq."

    Though vaccination programs typically focus on children, adults in
industrialized countries are more likely than children to die as a result
of vaccine-preventable diseases. For example, vaccines can prevent about
50% of deaths from pneumococcal disease and 80% of deaths from
influenza-related complications in the elderly. Immunization rates for
these diseases continue to be low in at-risk populations, but increased
educational efforts aiming to promote the benefits of immunization should
contribute to continued growth.

    Growth is also being fueled by vaccines that have recently been introduced
or are in the approval process that address meningitis, swine flu,
malaria, and Japanese encephalitis, as well as a growing number of
combination vaccines which are enjoying one of the highest growth rates
of any vaccine segment. Both Sanofi Pasteur's Penacel, which protects
against pertussis, diphtheria, tetanus, polio and Haemophilus influenzae
type B, and GlaxoSmithKline's Kimrix, which protects against pertussis,
diphtheria, tetanus and polio, were approved by the FDA in mid-2008.

    Kalorama Information's new report, "Vaccines 2009: World Market Analysis,
Key Players, and Critical Trends in a Fast-Changing Industry," covers all
the latest trends and issues for both pediatric and adult vaccines. Market
data is broken down by type of vaccine, and includes market size and
forecasts, product reviews and pipelines, and competitive analyses of
leading providers. For further information visit:

    About Kalorama Information

    Kalorama Information supplies the latest in independent market research in
the life sciences, as well as a full range of custom research services.


Please direct all media inquiries to:
Andrea Hiller

Copyright 2009, Market Wire, All rights reserved.



Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.